SLC5A2 and diabetes mellitus: Sodium-glucose cotransporter 2 (SGLT-2) has been used as a novel therapy for type 2 diabetes mellitus (T2DM), inhibiting the proximal renal tubular SGLT protein family reabsorption of glucose (8).